Form 4: Ironwood Pharmaceuticals Director Alexander Denner Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Alexander Denner, a director and 10% owner of Ironwood Pharmaceuticals, reported changes in beneficial ownership of Class A Common Stock, including acquisitions and disposals.
Summary
- On April 2, 2025, Alexander Denner reported changes in his beneficial ownership of Ironwood Pharmaceuticals' Class A Common Stock.
- He acquired 10,416 shares at $0, likely related to director compensation.
- He indirectly owns 16,390,000 shares through Sarissa Capital Management LP and related funds.
- Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
- A Limited Power of Attorney was executed on February 4, 2025, granting certain individuals the authority to file SEC forms on his behalf.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It simply reports transactions and grants a power of attorney.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.
Comparison to Industry Standards
- Form 4 filings are a standard regulatory requirement for publicly traded companies in the US, ensuring transparency of insider transactions.
- Similar filings are made by directors and officers of comparable pharmaceutical companies like Vertex Pharmaceuticals, Amgen, and Gilead Sciences, whenever they buy or sell shares of their respective companies.
Stakeholder Impact
- The filing provides transparency to shareholders regarding the transactions of a key insider, Alexander Denner.
- It assures stakeholders that insider transactions are being monitored and disclosed as required by regulations.
Key Dates
| Date | Description |
|---|---|
| 2024-01-01 | Effective date of the Second Amended and Restated Non-employee Director Compensation Policy. |
| 2025-02-04 | Date of execution of the Limited Power of Attorney. |
| 2025-04-02 | Date of the transaction involving the acquisition and disposal of Class A Common Stock. |
| 2025-04-04 | Date of signature of the report by Alexander Denner and Sarissa Capital Management LP. |
| 2025-12-31 | Expiration date of the Limited Power of Attorney, unless earlier revoked. |
Keywords
beneficial ownership, Form 4, Ironwood Pharmaceuticals, Alexander Denner, Sarissa Capital, securities, director, shares
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.